FDA hopes to use its compassionate use program to get potential COVID-19 therapies to health care providers and patients while also gathering information on safety and efficacy, agency chief Stephen Hahn announced Thursday (March 19) during a White House press briefing. Hahn and President Donald Trump both asserted the value of using the agency’s compassionate use program, also known as Expanded Access, over the Right to Try path saying it will allow the agency to collect more data on potential...